In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Watson acquires Actavis for €4.25bn, becoming third-largest generics company

Executive Summary

After months of speculation, Watson Pharmaceuticals Inc. has paid €4.25bn ($5.6bn) up front for privately held Actavis Group, creating the third-largest generics company in the world behind Teva and Sandoz. The deal includes $5.5bn in cash, the assumption of $132mm in debt, and an earn-out payment of 5.5mm Watson common shares (valued at $373mm) to be issued in 2013 if Actavis meets certain performance targets in 2012.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Payment Includes Stock
    • Includes Contract
    • Includes Earnout
    • Full Acquisition

Related Companies

UsernamePublicRestriction

Register